Page 3 - Nasdaq Aura News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Aura Biosciences (NASDAQ:AURA – Get Rating) and Scholar Rock (NASDAQ:SRRK – Get Rating) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, valuation, earnings, profitability, risk, analyst recommendations and dividends. Valuation & Earnings This table compares Aura Biosciences and […]

Aura Biosciences (NASDAQ:AURA – Get Rating) and Achilles Therapeutics (NASDAQ:ACHL – Get Rating) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, profitability, valuation, institutional ownership, dividends, risk and analyst recommendations. Profitability This table compares Aura Biosciences and Achilles Therapeutics’ […]

Aura Biosciences (NASDAQ:AURA – Get Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Friday, Zacks.com reports. According to Zacks, “Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy […]

Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) was the target of a significant increase in short interest in April. As of April 30th, there was short interest totalling 642,500 shares, an increase of 23.6% from the April 15th total of 519,900 shares. Currently, 3.6% of the company’s stock are short sold. Based on an average […]

Brokerages expect Aura Biosciences, Inc. (NASDAQ:AURA – Get Rating) to announce earnings of ($0.44) per share for the current quarter, according to Zacks. Zero analysts have provided estimates for Aura Biosciences’ earnings. The company is scheduled to announce its next quarterly earnings results on Monday, January 1st. According to Zacks, analysts expect that Aura Biosciences […]